Bull Run

India's AI-powered stock screener for NSE & BSE. 5,000+ stocks with fundamentals and real-time analysis.

info@bullrun.co.in

Navigate

  • Home
  • Smart Screener
  • Stock Battle Arena
  • Watchlist
  • Go Premium

Tools

  • Advanced Stock Screening
  • Stock Comparison Tool
  • Personal Watchlist
  • Ask AI Assistant
  • Browse All Stocks
  • IPO GMP Tracker
  • Market News & Blog

Indices

  • All Indices
  • Nifty 50 Stocks
  • Sensex Stocks
  • Nifty Bank
  • Nifty IT
  • Nifty Pharma
  • Nifty Midcap 100

Screeners

  • Top Dividend Stocks
  • Debt Free Stocks
  • Undervalued Stocks
  • High ROE Stocks
  • Low PE Stocks
  • Top Rated Stocks
  • Large Cap Stocks
  • Compare Stocks
  • Browse by Sector

Browse Stocks by Sector

View All →
Non Banking Financial Company (NBFC)PharmaceuticalsComputers - Software & ConsultingIndustrial ProductsCivil ConstructionAuto Components & EquipmentsSpecialty ChemicalsOther Financial ServicesIT Enabled ServicesPackagingHotels & ResortsCommodity ChemicalsOther Electrical EquipmentGarments & ApparelsPaper & Paper ProductsSoftware ProductsPackaged FoodsCement & Cement ProductsSugarHeavy Electrical EquipmentHospitalEdible OilPower GenerationHealthcare Service Provider
© 2026 Bull Run. All rights reserved.
AboutBlogPrivacy PolicyTerms of Service

Disclaimer: Ratings and scores are generated algorithmically from publicly available market data for educational and informational purposes only. They do not constitute investment advice or solicitation to buy/sell securities. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.

  1. Home
  2. /
  3. Sectors
  4. /
  5. Pharmaceuticals
  6. /
  7. Colinz Laboratories Ltd
Financial RatiosPE RatioShareholdingDividendQuarterly ResultsBalance SheetProfit & LossCash Flow
HomeStocksPharmaceuticalsColinz Laboratories Ltd

Colinz Laboratories Ltd Stock Price Today (NSE: COLINZ)

Colinz Laboratories Ltd

COLINZPharmaceuticals
₹44.50+₹0.00 (+0.00%)↑
As on 30 Mar 2026, 12:05 pm ISTMarket Closed

Fundamental Score

...

Colinz Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Colinz Laboratories Ltd share price today is ₹44.50, up +0.00% on NSE/BSE as of 30 March 2026. Colinz Laboratories Ltd (COLINZ) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹18.19 (Cr). The 52-week high for COLINZ share price is ₹87.91 and the 52-week low is ₹36.11. At a P/E ratio of 39.55x, COLINZ is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 5.43% and a debt-to-equity ratio of 0.07.

Colinz Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
₹0.00
Low
₹0.00
Volume
0
Change
+0.00%

Returns & Performance

Poor

ROE

5.43%
Poor

ROCE

6.72%
Poor

OPM (5Y)

7.65%

Div Yield

0.00%

Colinz Laboratories Ltd Valuation Check

Poor

P/E Ratio

39.55x
Poor

Industry P/E

31.77x
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Market Cap

18.19 (Cr)

Growth Engine

Poor

Profit Growth (Q)

-12.50%
Poor

Sales Growth (Q)

-25.27%
Poor

Sales Growth (5Y)

-2.81%
Excellent

EPS Growth (5Y)

30.92%
Excellent

Profit Growth (5Y)

30.92%

Balance Sheet Health

Excellent

Debt to Equity

0.07x
Excellent

Int. Coverage

12.80x

Free Cash Flow (5Y)

2.15 (Cr)

Shareholding

Excellent

Promoter

66.00%
Poor

FII

0.00%
Poor

DII

0.00%
Excellent

Pledged

0.00%

Institutional Deep-Dive

Bull Run Research Hub

Colinz Laboratories Share Price: A ROCE Efficiency Analysis

The pharmaceutical industry, while generally considered defensive, faces unique pressures regarding research & development (R&D) efficiency. High R&D spend is crucial, but converting that investment into profitable products defines long-term success. This financial analysis examines Colinz Laboratories share price, currently trading at ₹63.5 with a Price-to-Earnings (PE) ratio of 39.55 and a Return on Capital Employed (ROCE) of 6.72%. This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra.

The relatively high PE ratio suggests market expectations of future growth for Colinz Laboratories Ltd. However, the ROCE of 6.72% warrants closer inspection. ROCE measures how effectively a company uses its capital to generate profits. A lower ROCE, as observed here, might indicate inefficiencies in capital allocation, potentially stemming from higher costs, lower sales relative to invested capital, or less effective pricing strategies. This directly impacts the company's competitive moat, as a lower ROCE makes it harder to reinvest profits for growth, innovate, or maintain a price advantage.

When comparing Colinz Laboratories Ltd. to sector peers, a more nuanced picture emerges. Consider Mankind Pharma Ltd. Although a direct comparison necessitates a deeper dive into specific product portfolios and market segments, differences in ROCE between Colinz Laboratories and peers like Mankind Pharma Ltd. can often be attributed, in part, to perceived differences in management quality. Effective management teams typically demonstrate superior capital allocation skills, leading to higher ROCE and potentially a stronger market position. Understanding these qualitative aspects alongside quantitative data is crucial for a holistic assessment.

Ultimately, while the current Colinz Laboratories share price reflects market sentiment, the 6.72% ROCE presents an area for potential improvement. Monitoring the company's future performance, particularly its ability to enhance capital efficiency and generate higher returns on invested capital, will be crucial in determining its long-term investment value. Further investigation into specific cost drivers, revenue generation strategies, and capital expenditure plans would provide valuable insights into the company's ability to strengthen its financial performance and solidify its competitive standing.

SM
Analysis by Sweta Mishra
SEBI Registered Research Analyst

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Colinz Laboratories Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of COLINZ across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Excellent EPS Growth (30.92% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (30.92% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.07)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (12.80x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (66.00%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

6 factors identified

Below-Average Return on Equity (5.43%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (6.72%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Profit Decline Concern (-12.50%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-25.27%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-2.81% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Colinz Laboratories Ltd Financial Statements

Comprehensive financial data for Colinz Laboratories Ltd including income statement, balance sheet and cash flow

About COLINZ (Colinz Laboratories Ltd)

Colinz Laboratories Ltd is a pioneering force in the pharmaceutical landscape, dedicated to the research, development, and distribution of innovative healthcare solutions. With a s...teadfast commitment to improving patient outcomes, COLINZ specializes in crafting high-quality pharmaceutical formulations designed to address a wide spectrum of medical needs. Our state-of-the-art facilities and rigorous quality control measures ensure that every product meets the highest industry standards, providing reliable and effective treatments for diverse patient populations. COLINZ is driven by a passion for scientific advancement and a deep understanding of the evolving healthcare landscape, positioning us as a trusted partner for healthcare professionals and patients alike. COLINZ possesses a comprehensive portfolio encompassing a diverse array of pharmaceutical formulations, catering to various therapeutic areas. From conventional dosage forms such as tablets, capsules, and liquids to specialized delivery systems like injectables and topical ointments, we strive to provide versatile treatment options tailored to individual patient needs. COLINZ is deeply committed to providing comprehensive and effective healthcare solutions. Our strategically focused product lines encompass key therapeutic areas, including women's health, cardiovascular care, and gastrointestinal disorders. Our targeted approach allows us to leverage our expertise and resources to deliver specialized treatments that address the unique challenges within these critical healthcare domains. COLINZ is dedicated to pushing the boundaries of pharmaceutical innovation and improving the lives of patients through groundbreaking therapies. Our comprehensive range of allopathic products includes specialized oncology medications, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate and doxorubicin. Our dedication to research and development enables us to bring cutting-edge treatments to market, empowering healthcare professionals with the tools they need to combat serious illnesses. COLINZ is more than just a pharmaceutical company; we are a partner in health, committed to making a tangible difference in the lives of patients around the world.

Company Details

Symbol:COLINZ
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:https://www.colinz.com

Key Leadership

Dr. Narayanan Kutty Menon
CEO & Whole-Time Director
Mr. Ganesh S. Chitte
Chief Financial Officer
Ms. Falguni Kumawat
Company Secretary & Compliance Officer

Latest News

Colinz Laboratories Grants Authority for Factory Sale and Appoints New Company Secretary - scanx.trade
scanx.trade• 11/27/2025
Colinz Laboratories standalone net profit declines 12.50% in the September 2025 quarter - Business Standard
Business Standard• 11/4/2025
Colinz Laboratories Founder Director Dr. Mani L.S. Passes Away; Company to Appoint New Compliance Officer - scanx.trade
scanx.trade• 11/8/2025

COLINZ Share Price: Frequently Asked Questions

What is the current share price of Colinz Laboratories Ltd (COLINZ)?

As of 30 Mar 2026, 12:05 pm IST, Colinz Laboratories Ltd share price is ₹44.50. The COLINZ stock has a market capitalisation of ₹18.19 (Cr) on NSE/BSE.

Is COLINZ share price Overvalued or Undervalued?

COLINZ share price is currently trading at a P/E ratio of 39.55x, compared to the industry average of 31.77x. Based on this relative valuation, the Colinz Laboratories Ltd stock appears to be Overvalued against its sector peers.

What is the 52-week high and low of COLINZ share price?

The 52-week high of COLINZ share price is ₹87.91 and the 52-week low is ₹36.11. These values are updated daily from NSE/BSE price data.

What factors affect the Colinz Laboratories Ltd share price?

Key factors influencing COLINZ share price include quarterly earnings growth (Sales Growth: -25.27%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Colinz Laboratories Ltd a good stock for long-term investment?

Colinz Laboratories Ltd shows a 5-year Profit Growth of 30.92% and an ROE of 5.43%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.07 before investing in COLINZ shares.

How does Colinz Laboratories Ltd compare with its industry peers?

Colinz Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare COLINZ share price P/E of 39.55x and ROE of 5.43% against the industry averages to determine competitive standing.

What is the P/E ratio of COLINZ and what does it mean?

COLINZ share price has a P/E ratio of 39.55x compared to the industry average of 31.77x. Investors pay ₹40 for every ₹1 of annual earnings.

How is COLINZ performing according to Bull Run's analysis?

COLINZ has a Bull Run fundamental score of 33.7/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.

What sector and industry does COLINZ belong to?

COLINZ operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Colinz Laboratories Ltd share price.

What is Return on Equity (ROE) and why is it important for COLINZ?

COLINZ has an ROE of 5.43%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Colinz Laboratories Ltd generates profits from shareholders capital.

How is COLINZ debt-to-equity ratio and what does it indicate?

COLINZ has a debt-to-equity ratio of 0.07, which indicates conservative financing with low financial risk.

What is COLINZ dividend yield and is it a good dividend stock?

COLINZ offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Colinz Laboratories Ltd shares.

How has COLINZ share price grown over the past 5 years?

COLINZ has achieved 5-year growth rates of: Sales Growth -2.81%, Profit Growth 30.92%, and EPS Growth 30.92%.

What is the promoter holding in COLINZ and why does it matter?

Promoters hold 66.00% of COLINZ shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Colinz Laboratories Ltd.

What is COLINZ market capitalisation category?

COLINZ has a market capitalisation of ₹18 crores, placing it in the Small-cap category.

How volatile is COLINZ stock?

COLINZ has a beta of N/A. A beta > 1 suggests the Colinz Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is COLINZ operating profit margin trend?

COLINZ has a 5-year average Operating Profit Margin (OPM) of 7.65%, indicating the company's operational efficiency.

How is COLINZ quarterly performance?

Recent quarterly performance shows Colinz Laboratories Ltd YoY Sales Growth of -25.27% and YoY Profit Growth of -12.50%.

What is the institutional holding pattern in COLINZ?

COLINZ has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Colinz Laboratories Ltd stock.

HomeScreenerBattleWatchlist

Frequently Asked Questions about Colinz Laboratories Ltd

What is the current share price of Colinz Laboratories Ltd?

Colinz Laboratories Ltd (COLINZ) trades at ₹44.50 on NSE and BSE. Market cap ₹18.19 (Cr). Educational data only.

What is the P/E ratio of Colinz Laboratories Ltd?

Colinz Laboratories Ltd has a P/E of 39.55x vs industry average 31.77x.

What is the Bull Run score for Colinz Laboratories Ltd?

Colinz Laboratories Ltd has a Bull Run score of 33.7/100 based on 25+ financial parameters.

Does Colinz Laboratories Ltd pay dividends?

Colinz Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Colinz Laboratories Ltd?

Colinz Laboratories Ltd has ROE of 5.43%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Colinz Laboratories Ltd?

Colinz Laboratories Ltd has debt-to-equity of 0.07.

Is Colinz Laboratories Ltd a good investment?

Bull Run gives Colinz Laboratories Ltd a score of 33.7/100. This is not investment advice — consult a SEBI-registered advisor.